Welcome to our dedicated news page for Lexaria Bioscience (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexaria Bioscience 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexaria Bioscience 's position in the market.
News
Rhea-AI Summary
Lexaria Bioscience Corp. announces a registered direct offering and private placement of common stock and warrants, aiming to raise funds for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.23%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. has submitted an Investigational New Drug application with the FDA for its U.S. phase 1b hypertension clinical trial of DehydraTECH-CBD. The company has successfully sponsored five human clinical studies, showing significant reductions in blood pressure. The FDA has a 30-day review period before the trial can commence, and Lexaria is eager to start pending funding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. CEO Chris Bunka provides an annual letter to stakeholders, discussing the challenges faced in 2023 due to capital market conditions and the positive advancements made by the company. Despite the decline in stock price, Lexaria managed to raise capital to fund operations and maintain its Nasdaq listing. The company also welcomed new shareholders and filed a Form S-8 Registration Statement to register additional shares under the Incentive Equity Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
Rhea-AI Summary
Lexaria Bioscience Corp. announces an extensive planned research program to evaluate the DehydraTECH drug delivery platform for GLP-1 drugs, aiming to support potential commercial partnerships. The program includes human and animal studies on semaglutide, liraglutide, and tirzepatide, with the goal of improving oral delivery and stability of these drugs. The company aims to address the market need for enhanced performance and broader oral delivery of GLP-1 drugs, as well as to determine the commercial applicability of DehydraTECH to these drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. (LEXX) announces the availability of a broadcast titled 'Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.' The company's patented DehydraTECH platform aims to improve the way active molecules enter the bloodstream upon oral ingestion, potentially revolutionizing the treatment of various human afflictions. With numerous proven and potential blockbuster indications, Lexaria's innovative approach has the potential to supercharge the impact of GLP-1 agonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces its placement in an editorial discussing the potential therapeutic uses of GLP-1 drugs, including treatment for type 2 diabetes, weight loss, Alzheimer’s, Parkinson’s, drug addiction, heart disease, chronic kidney disease, and more. The company aims to improve the delivery and efficacy of GLP-1 drugs with its DehydraTECH(TM) drug-delivery formulation and processing technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX & LEXXW) announces positive final results from a human Pilot Study #1 evaluating DehydraTECH technology for the oral delivery of the GLP-1 drug semaglutide. The study showed that DehydraTECH-powered semaglutide outperformed Rybelsus in terms of sustained higher levels of semaglutide in blood, better blood glucose control, faster achievement of peak drug delivery, and reduced side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announces the anticipated submission of an Investigational New Drug (IND) application with the U.S. FDA for its planned U.S. Phase 1b Hypertension Clinical Trial, following a supplier-related delay. The company has conducted five human clinical trials studying DehydraTECH-CBD, showing significant reductions in resting blood pressure and zero serious adverse events, indicating potential clinical benefits. The latest study demonstrated a potentially novel mechanism of action of DehydraTECH-CBD in reducing blood pressure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
-
Rhea-AI Summary
Lexaria Bioscience Corp. (LEXX) announces positive interim results from a human pilot study evaluating DehydraTECH technology for the oral delivery of the GLP-1 drug semaglutide. The study shows sustained lower levels of blood glucose, a lower blood-glucose spike after eating, and a successful first-ever DehydraTECH test with a 'large molecule' drug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
Rhea-AI Summary
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, 'Can Diabetes, Weight-Loss Drugs Get Even Better?' The global diabetes drug market is estimated to be $63.1 billion in 2021 and expected to reach $82.93 billion in 2027. The market for diabetes devices is valued at $26.1 billion and growing 7.5% annually. Lexaria's DehydraTECH diabetes-related studies have shown positive effects in lowering glucose levels, body weight, and triglyceride levels, as well as increased locomotor activity. The company plans to expand its diabetes study program using DehydraTECH for GLP-1 drugs alone and in combination with other molecules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
Lexaria Bioscience Corp.
Nasdaq:LEXX
LEXX Rankings
LEXX Stock Data
44.97M
11.14M
8.58%
9%
3.87%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
KELOWNA
About LEXX
learn about working at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group. join linkedin today for free. see who you know at legal adviser at sbde . co , legal adviser for mr mohamed kaaki, ceo for oversease business group, leverage your professional network, and get hired.